Angiogenesis inhibitors in the treatment of lung cancer

Sophie Sun, Joan H. Schiller

Research output: Contribution to journalReview article

43 Scopus citations

Abstract

Despite improvements in cytotoxic chemotherapy and combined modality therapies for lung cancer, the prognosis for patients remains poor, and the majority of patients die from the disease. Angiogenesis, i.e. the formation of new blood vessels, is important for tumor growth, invasion and metastasis and represents a rational target in the development of more effective treatments. The vascular endothelial growth factor (VEGF) signaling pathway plays a crucial role in the angiogenic process and consequently, inhibitors of this system are currently under development. The most studied anti-angiogenic agents include anti-VEGF monoclonal antibodies and VEGF receptor tyrosine kinase inhibitors. Recent clinical trials have yielded promising results. This article will review angiogenesis inhibitors targeting the VEGF pathway which are currently being developed for the treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)93-104
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume62
Issue number2
DOIs
StatePublished - May 1 2007

Keywords

  • Angiogenesis inhibitors
  • Lung cancer
  • Tyrosine kinase inhibitors
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Angiogenesis inhibitors in the treatment of lung cancer'. Together they form a unique fingerprint.

  • Cite this